BR112022021884A2 - Proteínas que se ligam a nkg2d, cd16 e clec12a - Google Patents

Proteínas que se ligam a nkg2d, cd16 e clec12a

Info

Publication number
BR112022021884A2
BR112022021884A2 BR112022021884A BR112022021884A BR112022021884A2 BR 112022021884 A2 BR112022021884 A2 BR 112022021884A2 BR 112022021884 A BR112022021884 A BR 112022021884A BR 112022021884 A BR112022021884 A BR 112022021884A BR 112022021884 A2 BR112022021884 A2 BR 112022021884A2
Authority
BR
Brazil
Prior art keywords
clec12a
bind
nkg2d
proteins
multispecific binding
Prior art date
Application number
BR112022021884A
Other languages
English (en)
Inventor
Baruah Hemanta
P Chang Gregory
F Cheung Ann
Fallon Daniel
Grinberg Asya
Sean Juo Zong
Ryan Morgan Christopher
Original Assignee
Dragonfly Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Dragonfly Therapeutics Inc filed Critical Dragonfly Therapeutics Inc
Publication of BR112022021884A2 publication Critical patent/BR112022021884A2/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2851—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the lectin superfamily, e.g. CD23, CD72
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39591—Stabilisation, fragmentation
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/283—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against Fc-receptors, e.g. CD16, CD32, CD64
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/515—Complete light chain, i.e. VL + CL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C07K2317/53—Hinge
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/55—Fab or Fab'
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/64—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising a combination of variable region and constant region components
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)

Abstract

PROTEÍNAS QUE SE LIGAM A NKG2D, CD16 E CLEC12A. A presente invenção refere-se a proteínas de ligação multiespecíficas que se ligam a receptor de NKG2D, CD16 e CLEC12A, composições farmacêuticas que compreendem as proteínas de ligação multiespecíficas e métodos terapêuticos úteis para o tratamento de câncer.
BR112022021884A 2020-05-06 2021-05-05 Proteínas que se ligam a nkg2d, cd16 e clec12a BR112022021884A2 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US202063020798P 2020-05-06 2020-05-06
PCT/US2021/030821 WO2021226193A1 (en) 2020-05-06 2021-05-05 Proteins binding nkg2d, cd16 and clec12a

Publications (1)

Publication Number Publication Date
BR112022021884A2 true BR112022021884A2 (pt) 2022-12-20

Family

ID=78468474

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112022021884A BR112022021884A2 (pt) 2020-05-06 2021-05-05 Proteínas que se ligam a nkg2d, cd16 e clec12a

Country Status (15)

Country Link
US (1) US20220119534A1 (pt)
EP (1) EP4146271A1 (pt)
JP (1) JP2023508942A (pt)
KR (1) KR20230008181A (pt)
CN (1) CN115836088A (pt)
AR (1) AR122018A1 (pt)
AU (1) AU2021268340A1 (pt)
BR (1) BR112022021884A2 (pt)
CA (1) CA3177024A1 (pt)
CL (1) CL2022003077A1 (pt)
CO (1) CO2022015929A2 (pt)
IL (1) IL297922A (pt)
MX (1) MX2022013944A (pt)
TW (1) TW202208428A (pt)
WO (1) WO2021226193A1 (pt)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP4050026A1 (en) * 2014-04-01 2022-08-31 Adimab, LLC Method of obtaining or identifying one or more common light chains for use in preparing a multispecific antibody
AU2018219887A1 (en) 2017-02-08 2019-08-22 Dragonfly Therapeutics, Inc. Multi-specific binding proteins for activation of natural killer cells and therapeutic uses thereof to treat cancer
ES2955074T3 (es) 2017-02-20 2023-11-28 Dragonfly Therapeutics Inc Proteínas que se unen a HER2, NKG2D Y CD16
BR112020016190A2 (pt) 2018-02-08 2020-12-15 Dragonfly Therapeutics, Inc. Domínios variáveis de anticorpos direcionando o receptor nkg2d
BR112020016939A2 (pt) * 2018-02-20 2020-12-15 Dragonfly Therapeutics, Inc. Proteínas de ligação multiespecíficas que se ligam a cd33, nkg2d, e cd16 e métodos de uso
WO2023107956A1 (en) * 2021-12-08 2023-06-15 Dragonfly Therapeutics, Inc. Proteins binding nkg2d, cd16 and 5t4
WO2023201238A1 (en) * 2022-04-11 2023-10-19 Vor Biopharma Inc. Binding agents and methods of use thereof

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9163090B2 (en) * 2012-05-07 2015-10-20 Cellerant Therapeutics, Inc. Antibodies specific for CLL-1
US20180326027A1 (en) * 2015-11-09 2018-11-15 The University Of British Columbia Epitopes in amyloid beta and conformationally-selective antibodies thereto
EP3851457A1 (en) * 2016-01-21 2021-07-21 Novartis AG Multispecific molecules targeting cll-1
JP2019535250A (ja) * 2016-10-29 2019-12-12 ジェネンテック， インコーポレイテッド 抗ｍｉｃ抗体及び使用方法
CA3112990A1 (en) * 2017-08-16 2019-02-21 Dragonfly Therapeutics, Inc. Proteins binding nkg2d, cd16, and egfr, ccr4, or pd-l1
AU2018322178A1 (en) * 2017-08-23 2020-02-20 Dragonfly Therapeutics, Inc. Proteins binding NKG2D, CD16 and a tumor-associated antigen
KR20200051789A (ko) * 2017-09-14 2020-05-13 드래곤플라이 쎄라퓨틱스, 인크. Nkg2d, cd16, 및 c-유형 렉틴-유사 분자-1 (cll-1)에 결합하는 단백질
WO2019164929A1 (en) * 2018-02-20 2019-08-29 Dragonfly Therapeutics, Inc. Antibody variable domains targeting cd33, and use thereof
CA3113539A1 (en) * 2018-10-10 2020-04-16 Zymeworks Inc. Antibody constructs binding 4-1bb and tumor-associated antigens and uses thereof
CN114929745A (zh) * 2019-10-17 2022-08-19 明尼苏达大学董事会 Clec12a抗体片段序列和方法

Also Published As

Publication number Publication date
JP2023508942A (ja) 2023-03-06
KR20230008181A (ko) 2023-01-13
CN115836088A (zh) 2023-03-21
WO2021226193A1 (en) 2021-11-11
CL2022003077A1 (es) 2023-07-21
IL297922A (en) 2023-01-01
US20220119534A1 (en) 2022-04-21
CA3177024A1 (en) 2021-11-11
MX2022013944A (es) 2022-11-30
AR122018A1 (es) 2022-08-03
EP4146271A1 (en) 2023-03-15
AU2021268340A1 (en) 2022-12-08
CO2022015929A2 (es) 2023-02-16
TW202208428A (zh) 2022-03-01

Similar Documents

Publication Publication Date Title
BR112022021884A2 (pt) Proteínas que se ligam a nkg2d, cd16 e clec12a
EA201892362A1 (ru) Агонистические антитела, которые связываются с cd40 человека, и варианты их применения
BR112019024654A2 (pt) proteína de ligação nkg2d, cd16 e ror1 ou ror2
MX2021002970A (es) Proteinas de union a nkg2d, cd16 y un antigeno asociado a tumor.
EP3882270A3 (en) Proteins binding nkg2d, cd16, and egfr, ccr4, or pd-l1
CL2020003071A1 (es) Proteínas de unión multiespecíficas y mejoras con estas
MX2019009848A (es) Proteínas que se unen a her2, nkg2d y cd16.
MX2019009566A (es) Proteinas de union a bcma, nkg2d y cd16.
BR112021019334A2 (pt) Anticorpos de cadeia pesada que se ligam ao psma
BR112022007128A2 (pt) Ligação de proteínas nkg2d, cd16 e flt3
BR112021023026A2 (pt) Moléculas de ligação biespecíficas anti-ror1/anti-cd3
BR112019012796A2 (pt) proteínas de ligação ao antígeno antineuropilina e métodos de uso das mesmas
BR112021024956A2 (pt) Anticorpos multiespecíficos de cadeia pesada que se ligam a cd22 e cd3
MX2020002036A (es) Proteinas de union a nkg2d, cd16 y un antigeno asociado al tumor.
CO2020001981A2 (es) Proteínas que se unen a nkg2d, cd16 y flt3
MX2019009541A (es) Proteinas que se unen a psma, nkg2d y cd16.
MX2019009943A (es) Proteínas que se unen a gd2, nkg2d y cd16.
CL2021000316A1 (es) Proteínas de unión multiespecíficas que se unen a bcma, nkg2d y cd16 y métodos de uso
MX2021000387A (es) Fragmentos de union a fc que comprenden un sitio de union al antigeno cd137.
BR112022008552A2 (pt) Moléculas de ligação multiespecíficas de scfv de terminal-n
BR112023002116A2 (pt) Proteínas que se ligam a nkg2d, cd16 e egfr
MX2019009847A (es) Proteínas que se unen a cd123, nkg2d y cd16.
WO2019100052A3 (en) Cd137 antibodies and tumor antigen-targeting antibodies and uses thereof
BR112022002761A2 (pt) Proteínas de ligação a 4-1bb e ox40 e composições e métodos relacionados, anticorpos contra 4-1bb, anticorpos contra ox40
BR112022005787A2 (pt) Proteínas de ligação a antígeno